NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
Acclaro Medical
United States
- Smithfield, RI
- 30/05/2025
- Series B
- $23,000,000
Founded in 2018 by world-class industry experts and top physicians in the nation, Acclaro Corporation is a US-based, VC-backed, fast-growing medical device company committed to innovating and developing game-changing solutions to address today’s most challenging unmet needs in the global medical aesthetic, ophthalmic and surgical markets.
Acclaro Medical’s flagship product, UltraClear® is the world’s first and only cold, ablative fiber laser platform, a breakthrough painless anti-aging solution and the first ablative laser not requiring topical numbing for most treatments. Powered by the revolutionary 3DMIRACL® and 3DIntelliPulse™ technologies, UltraClear® is a high-speed, all-skin-type and all-in-one platform with unparalleled energy control capabilities, offering a full range of skin rejuvenation outcomes from true painless and zero-downtime anti-aging lunchtime treatments to most advanced collagen remodeling with superior results, 15-min avg. treatment time and the utmost patient safety and comfort.
- Industry Medical Device
- Website https://ultraclearlaser.com/
- LinkedIn https://www.linkedin.com/company/acclaromedical/
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)